Qinlock (Ripretinib) Approved as Fourth-Line Treatment for GIST

MONDAY, May 18, 2020 -- The U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as a fourth-line treatment for adults with advanced gastrointestinal stromal tumors (GISTs), the agency announced Friday. The approval follows four...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news